Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
ClearNote Health Secures $52 Million in Series D Financing, led by Mattias Westman, to enhance early cancer detection efforts.
PRIVATEMay 27, 2026•2 months ago
Amount Raised
$52 Million
Round Type
Series D
San DiegoBiotechnologyHealth CareMedical DeviceHealth Diagnostics
Investors
Dr. Stephen QuakeSandy WeillMattias Westman
Description
ClearNote Health has announced the close of $52 million in Series D financing to bolster its efforts in early cancer detection. The financing will aid in commercial expansion, clinical study execution, and product development. This round was led by investor Mattias Westman, along with contributions from several institutional investors. CEO Dave Mullarkey expresses confidence in the company's growth trajectory and market opportunity.
Company Information
Company
ClearNote Health
Location
San Diego, California, United States
About
ClearNote Health is a privately held company dedicated to improving early detection and monitoring for some of the deadliest forms of cancer. Developed by scientists in the Stephen Quake laboratory at Stanford University, the company’s patented core Virtuoso® epigenomics platform utilizes advances in artificial intelligence and bioinformatics. Their noninvasive Avantect® tests are designed to identify cancers in high-risk patient populations far earlier than conventional approaches. ClearNote Health aims to enhance patient outcomes through innovative cancer detection technologies.
Related People
Suggested for you
4 contacts
Verified contactsMichele M., Strategic Accounts Director, West
Predictive Intelligence
Strategic
ML-powered predictions for ClearNote Health's next move
San DiegoBiotechnologyHealth CareMedical DeviceHealth Diagnostics